摘要:
Hybrid nanoparticles including a nanosphere with a mean diameter in the range 2-9 nm, of which at least 90 wt % consists of Ln2O3, where Ln is a rare earth optionally doped with a rare earth or an actinide, or a mixture of rare earths, or else a rare earth/actinide mixture in which at least 50 % of the metal ions are rare-earth ions; a coating around the nanosphere, of which a major part consists of a functionalised polysiloxane, and which has a mean thickness in the range 0.5-10 nm, preferably more than 2 nm but no more than 10 nm; and at least one bioligand grafted by a covalent bond to the polysiloxane coating; and a method for preparing same.
摘要:
The invention relates to hybrid particle probes, comprising a nanoparticle of gold with a diameter in the range 2 to 30 nm with at least one, preferably 1 to 100 organic probe molecules and at least 10, preferably 10 to 10,000 molecules with luminescent activity, grafted to the surface thereof, by means of gold-sulphur bonds and a method for production thereof.
摘要:
The invention relates to a method for producing a single-phase or multiphase powder, optionally in the form of a colloidal suspension of sesquioxide, oxohydroxide, hydroxide or pure rare-earth mixed oxide, while in a mixture or doped, the rare-earth portion representing more than 50 % of the mass of the obtained powder. The invention also relates to essentially spherical powder particles having a mean diameter ranging between 20 and 800 nm and being nanostructured of Ln2O3 and a colloidal suspension.
摘要:
L'invention concerne de nouvelles nanoparticules hybrides biocompatibles de très faible taille, utiles notamment pour le diagnostic et/ou la thérapie. Le but de l'invention est de proposer de nouvelles nanoparticules qui soient utiles notamment comme agents de contraste en imagerie (e.g. IRM) et/ou dans d'autres techniques de diagnostic et/ou comme agents de thérapie, qui soient plus performantes que les nanoparticules de même type connues et qui combinent à la fois une petite taille (par exemple inférieure à 20 nm) et un fort taux de charge en métaux (e.g. terres rares), en particulier pour avoir en imagerie (e.g. IRM) un fort rehaussement et une réponse correcte (relaxivité accrue) aux hautes fréquences. Ainsi, les nanoparticules selon l'invention, de diamètre d 1 entre 1 et 20 nm, comprennent chacune une matrice polyorganosiloxane (POS) incluant des cations gadolinium éventuellement associé à des cations dopants; un greffon C 1 chélatant DTPABA (dianydride d'acide diéthylènetriaminepentaacétique) lié à la matrice POS par liaison covalente -Si-C-, et présent en quantité suffisante pour pouvoir complexer tous les cations gadolinium; et éventuellement un autre greffon de fonctionnalisation Gf* lié à la matrice POS par liaison covalente -Si-C- (Gf* pouvant être issu d'un composé hydrophile (PEG); d'un composé comportant un principe actif PA1;d'un composé ciblant; d'un composé luminescent (fluorescéine). Le procédé d'obtention de ces nanoparticules et leurs applications en imagerie et en thérapie font également partie de l'invention.
摘要:
The invention relates to novel biocompatible hybrid nanoparticles of very small size that are of use in particular for diagnosis and/or therapy. The objective of the invention is to provide novel nanoparticles which are of use in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which are more effective than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high metal (e.g. rare earth) loading rate, in particular so as to have, in imaging (e.g. MRI), a strong enhancement and a correct response (increased relaxivity) at high frequencies. Thus, the nanoparticles according to the invention, of diameter d 1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations, optionally associated with doping cations; a DTPABA (diethylenetriaminepentaacetic acid bisanhydride) chelating C 1 graft bonded to the POS matrix via -Si-C- covalent bonding, and present in sufficient amount to be able to complex all the gadolinium cations; and optionally an other functionalization graft Gf* bonded to the POS matrix via -Si-C- covalent bonding (it being possible for Gf* to result from a hydrophilic compound (PEG); from a compound comprising an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein)). The method for obtaining these nanoparticles and the uses thereof in imaging and in therapy are also part of the invention.
摘要:
The invention relates to coding products comprising mixed lanthanide compounds, in particular mixed lanthanide oxides. The invention also relates to the use of said coding products for the authentication of value documents.